Eicosanoids and the vascular endothelium.

[1]  T. Matsui,et al.  Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor. , 2006, Cardiovascular drug reviews.

[2]  G. FitzGerald,et al.  Genetic model of selective COX2 inhibition reveals novel heterodimer signaling , 2006, Nature Medicine.

[3]  Ying Yu,et al.  Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. , 2006, The Journal of clinical investigation.

[4]  J. Segal,et al.  Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men , 2006, Journal of the American Medical Association (JAMA).

[5]  A. Sacchetti,et al.  De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin , 2006, Circulation research.

[6]  Rongsong Li,et al.  Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC , 2006, Circulation research.

[7]  J. Morrow.  The isoprostanes - unique products of arachidonate peroxidation: their role as mediators of oxidant stress. , 2006, Current pharmaceutical design.

[8]  S. Narumiya,et al.  Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis , 2006, The Journal of experimental medicine.

[9]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[10]  Rajesh C. Dash,et al.  Prostacyclin protects against elevated blood pressure and cardiac fibrosis. , 2005, Cell metabolism.

[11]  E. Ricciotti,et al.  Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.

[12]  B. Masereel,et al.  In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  Dairong Wang,et al.  Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.

[14]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[15]  J. Morrow,et al.  Oxidant stress but not thromboxane decreases with epoprostenol therapy. , 2005, Free radical biology & medicine.

[16]  Hiroshi Kadotani,et al.  Resetting of peripheral circadian clock by prostaglandin E2 , 2005, EMBO reports.

[17]  E. Puré,et al.  Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism , 2005, Circulation.

[18]  Stephen J. Wilson,et al.  Dimerization of the Human Receptors for Prostacyclin and Thromboxane Facilitates Thromboxane Receptor-mediated cAMP Generation* , 2004, Journal of Biological Chemistry.

[19]  D. Rader,et al.  COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice , 2004, Science.

[20]  Tom S. Price,et al.  Prostaglandin E Synthases in Zebrafish , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  Shinn-Zong Lin,et al.  EP1- and EP3-Receptors Mediate Prostaglandin E2–Induced Constriction of Porcine Large Cerebral Arteries , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  M. Gatzoulis,et al.  Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities. , 2004, International journal of cardiology.

[23]  J. Morrow,et al.  Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. , 2004, Analytical biochemistry.

[24]  G. FitzGerald.  Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[25]  J. Morrow,et al.  Signaling through the Prostaglandin I2 Receptor IP Protects against Respiratory Syncytial Virus-Induced Illness , 2004, Journal of Virology.

[26]  P. Serruys,et al.  No change in endothelial-dependent vasomotion late after coronary irradiation. , 2004, Cardiovascular radiation medicine.

[27]  C. Hennekens,et al.  Terms and Conditions: Semantic Complexity and Aspirin Resistance , 2004, Circulation.

[28]  S. Narumiya,et al.  Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. , 2004, The Journal of clinical investigation.

[29]  S. Narumiya,et al.  Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice , 2004 .

[30]  V. Fuster,et al.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[31]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[32]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[33]  A. Ashton,et al.  Thromboxane A2 Receptor Signaling Inhibits Vascular Endothelial Growth Factor–Induced Endothelial Cell Differentiation and Migration , 2004, Circulation research.

[34]  R. Breyer,et al.  Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. , 2004, Pharmacology & therapeutics.

[35]  P. Kolh,et al.  New developments on thromboxane modulators. , 2004, Mini reviews in medicinal chemistry.

[36]  Shu-Wha Lin,et al.  TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. , 2004, Blood.

[37]  A. Maguire,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population , 2004, Circulation.

[38]  C. Patrono,et al.  Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects , 2004, Circulation.

[39]  G. FitzGerald,et al.  F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. , 2004, Chemistry and physics of lipids.

[40]  D. Rader,et al.  Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. , 2004, The Journal of clinical investigation.

[41]  C. Patrono,et al.  Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[42]  D. Dixon.  Dysregulated post-transcriptional control of COX-2 gene expression in cancer. , 2004, Current pharmaceutical design.

[43]  F. Fitzpatrick,et al.  Cyclooxygenase enzymes: regulation and function. , 2004, Current pharmaceutical design.

[44]  J. Regan,et al.  Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. , 2004, Archives of biochemistry and biophysics.

[45]  B. Koller,et al.  Proinflammatory Actions of Thromboxane Receptors to Enhance Cellular Immune Responses 1 , 2003, The Journal of Immunology.

[46]  Garret A. FitzGerald,et al.  COX-2 and beyond: approaches to prostaglandin inhibition in human disease , 2003, Nature Reviews Drug Discovery.

[47]  A. Morrison,et al.  The Proximal Region of the 3′-Untranslated Region of Cyclooxygenase-2 is Recognized by a Multimeric Protein Complex Containing HuR, TIA-1, TIAR, and the Heterogeneous Nuclear Ribonucleoprotein U* , 2003, Journal of Biological Chemistry.

[48]  C. Saper,et al.  Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. , 2003, The Journal of physiology.

[49]  M. Reilly,et al.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. , 2003, The Journal of clinical investigation.

[50]  H. Hirai,et al.  The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[51]  K. Katagiri,et al.  Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity , 2003, Nature Immunology.

[52]  P. Patrignani.  Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. , 2003, Thrombosis research.

[53]  M. Sutton,et al.  COX-2–Dependent Cardiac Failure in Gh/tTG Transgenic Mice , 2003, Circulation research.

[54]  T. Matsui,et al.  Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. , 2003, European journal of pharmacology.

[55]  P. Libby,et al.  Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor* , 2002, The Journal of Biological Chemistry.

[56]  S. Dey,et al.  A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. , 2002, Endocrinology.

[57]  S. Ito,et al.  Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. , 2002, American journal of physiology. Renal physiology.

[58]  S. Narumiya,et al.  Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells , 2002, British journal of pharmacology.

[59]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[60]  D. Fitzgerald,et al.  Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. , 2002, The Journal of pharmacology and experimental therapeutics.

[61]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[62]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[63]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[64]  S. Narumiya,et al.  Roles of Prostaglandin I2 and Thromboxane A2 in Cardiac Ischemia-Reperfusion Injury: A Study Using Mice Lacking Their Respective Receptors , 2001, Circulation.

[65]  M. Murakami,et al.  Coupling between Cyclooxygenase, Terminal Prostanoid Synthase, and Phospholipase A2 * , 2001, The Journal of Biological Chemistry.

[66]  D. Fitzgerald,et al.  Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. , 2001, The Journal of clinical investigation.

[67]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[68]  G. FitzGerald,et al.  Genetic and pharmacological analysis of prostanoid receptor function. , 2001, The Journal of clinical investigation.

[69]  G. FitzGerald,et al.  Prostaglandin F2α Receptor-Dependent Regulation of Prostaglandin Transport , 2001 .

[70]  S. Narumiya,et al.  Characterization of EP receptor subtypes responsible for prostaglandin E2‐induced pain responses by use of EP1 and EP3 receptor knockout mice , 2001, British journal of pharmacology.

[71]  G. FitzGerald,et al.  COX in a crystal ball: current status and future promise of prostaglandin research. , 2001, The Journal of clinical investigation.

[72]  G. FitzGerald,et al.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. , 2001, The Journal of clinical investigation.

[73]  G. FitzGerald,et al.  Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. , 2000, Blood.

[74]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[75]  Makoto Murakami,et al.  Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2* , 2000, The Journal of Biological Chemistry.

[76]  Makoto Murakami,et al.  Molecular Identification of Cytosolic Prostaglandin E2 Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E2Biosynthesis* , 2000, The Journal of Biological Chemistry.

[77]  R. Cohen,et al.  The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[78]  G. FitzGerald,et al.  TP or not TP: primary mediators in a close runoff? , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[79]  G. FitzGerald,et al.  Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo , 2000 .

[80]  G. FitzGerald,et al.  Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation , 2000, Nature Medicine.

[81]  P. Libby,et al.  Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.

[82]  L. Audoly,et al.  Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. , 1999, American journal of physiology. Heart and circulatory physiology.

[83]  L. Marnett,et al.  Arachidonic Acid Oxygenation by COX-1 and COX-2 , 1999, The Journal of Biological Chemistry.

[84]  G. FitzGerald,et al.  Not a mouse stirring: deletion of the EP2 and love's labor's lost. , 1999, The Journal of clinical investigation.

[85]  H. S. Kim,et al.  Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. , 1999, The Journal of clinical investigation.

[86]  G. FitzGerald,et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.

[87]  Sharon R. Adderley,et al.  Oxidative Damage of Cardiomyocytes Is Limited by Extracellular Regulated Kinases 1/2-mediated Induction of Cyclooxygenase-2* , 1999, The Journal of Biological Chemistry.

[88]  M. Aoki,et al.  Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. , 1999, Stroke.

[89]  G. FitzGerald,et al.  Phosphorylation of the Thromboxane Receptor α, the Predominant Isoform Expressed in Human Platelets* , 1999, The Journal of Biological Chemistry.

[90]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[91]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[92]  P. Mannon,et al.  Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. , 1998, The Journal of clinical investigation.

[93]  B. Koller,et al.  Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. , 1998, American journal of physiology. Renal physiology.

[94]  J. Gómez-Reino,et al.  Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. , 1998, British journal of rheumatology.

[95]  J. W. Woods,et al.  Subcellular Localization of Prostaglandin Endoperoxide H Synthases-1 and -2 by Immunoelectron Microscopy* , 1998, The Journal of Biological Chemistry.

[96]  A. Ford-hutchinson,et al.  Characterization of the recombinant human prostanoid DP receptor and identification of L‐644,698, a novel selective DP agonist , 1998, British journal of pharmacology.

[97]  T. Grosser,et al.  Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. , 1998, European journal of pharmacology.

[98]  B. Koller,et al.  The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth , 1997, Nature.

[99]  G. FitzGerald,et al.  Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. , 1997, The Journal of biological chemistry.

[100]  R. Pakala,et al.  Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. , 1997, Circulation.

[101]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[102]  C. Leslie.  Properties and Regulation of Cytosolic Phospholipase A2 * , 1997, The Journal of Biological Chemistry.

[103]  V. Ullrich,et al.  Tyrosine Nitration as a Mechanism of Selective Inactivation of Prostacyclin Synthase by Peroxynitrite , 1997, Biological chemistry.

[104]  S. Moncada,et al.  Bioassay of prostacyclin and endothelium‐derived relaxing factor (EDRF) from porcine aortic endothelial cells , 1997, British journal of pharmacology.

[105]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[106]  M. Gimbrone,et al.  Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[107]  S. Narumiya,et al.  Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. , 1996, The Journal of clinical investigation.

[108]  H. Herschman.  Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.

[109]  Daniel Picot,et al.  The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase , 1995, Nature Structural Biology.

[110]  B. Belletti,et al.  Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells. , 1995, Experimental cell research.

[111]  S. Narumiya,et al.  cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. , 1994, The Journal of biological chemistry.

[112]  Y. Boie,et al.  Cloning and expression of a cDNA for the human prostanoid IP receptor. , 1994, The Journal of biological chemistry.

[113]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[114]  S. Narumiya,et al.  Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. , 1993, The Journal of biological chemistry.

[115]  Michael G. Davis,et al.  Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. , 1993, The Journal of biological chemistry.

[116]  C. Yokoyama,et al.  Molecular cloning and expression of human thromboxane synthase. , 1993, Journal of lipid mediators.

[117]  L. L. Lin,et al.  Interleukin-1 alpha induces the accumulation of cytosolic phospholipase A2 and the release of prostaglandin E2 in human fibroblasts. , 1992, The Journal of biological chemistry.

[118]  S. Narumiya,et al.  Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. , 1992, Biochemical and biophysical research communications.

[119]  G. FitzGerald,et al.  Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. , 1991, The New England journal of medicine.

[120]  G. FitzGerald.  Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.

[121]  G. FitzGerald,et al.  Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[122]  S. Nakanishi,et al.  Cloning and expression of cDNA for a human thromboxane A2 receptor , 1991, Nature.

[123]  G. FitzGerald,et al.  Thromboxane A2 synthesis in pregnancy-induced hypertension , 1990, The Lancet.

[124]  G. Dorn,et al.  Cultured human vascular smooth muscle cells with functional thromboxane A2 receptors: measurement of U46619-induced 45calcium efflux. , 1987, Circulation research.

[125]  G. FitzGerald,et al.  Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. , 1987, Circulation.

[126]  G. FitzGerald,et al.  11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[127]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[128]  G. FitzGerald,et al.  Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography--negative-ion chemical ionization mass spectrometry. , 1985, Analytical biochemistry.

[129]  W. C. Still,et al.  Synthesis and structure of the platelet aggregation factor thromboxane A2 , 1985, Nature.

[130]  H. Patscheke.  Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid. , 1985, Biochemical pharmacology.

[131]  G. FitzGerald,et al.  Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. , 1984, The New England journal of medicine.

[132]  J. Oates,et al.  Metabolic disposition of prostacyclin in humans. , 1983, The Journal of pharmacology and experimental therapeutics.

[133]  G. FitzGerald,et al.  Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. , 1983, Circulation.

[134]  B. Weksler,et al.  Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells. , 1982, The Journal of clinical investigation.

[135]  J. Oates,et al.  Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.

[136]  J. Oates,et al.  Increased production of prostaglandin D2 in patients with systemic mastocytosis. , 1980, The New England journal of medicine.

[137]  G. Fitzgerald,et al.  A double blind placebo controlled crossover study of prostacyclin in man. , 1979, Life sciences.

[138]  A. Szczeklik,et al.  SUCCESSFUL THERAPY OF ADVANCED ARTERIOSCLEROSIS OBLITERANS WITH PROSTACYCLIN , 1979, The Lancet.

[139]  J. Vane,et al.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. , 1978, Pharmacological reviews.

[140]  J. Vane,et al.  Relative potency of prostacyclin, prostaglandin E1 and D2 as inhibitors of platelet aggregation in several species [proceedings]. , 1977, The Journal of physiology.

[141]  J. Oates,et al.  Metabolism of thromboxane B2 in man. Identification of the major urinary metabolite. , 1977, The Journal of biological chemistry.

[142]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[143]  M. Hamberg,et al.  Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides , 1976, Nature.

[144]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[145]  A. Jacobs,et al.  Aspirin resistance: current concepts. , 2004, Reviews in cardiovascular medicine.

[146]  G. FitzGerald,et al.  Human prostacyclin receptor. , 2002, Vitamins and hormones.

[147]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[148]  Yusuke Nakamura,et al.  Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association of a T924C polymorphism in the thromboxane A2 receptor gene , 2000, Human Genetics.

[149]  P. Loll,et al.  The 3.1 A X-ray crystal structure of the integral membrane enzyme prostaglandin H2 synthase-1. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

[150]  J. Morrow,et al.  Formation of PGD2 after allergen inhalation in atopic asthmatics. , 1991, Advances in prostaglandin, thromboxane, and leukotriene research.

[151]  Gerritsen Me.  Eicosanoid production by the coronary microvascular endothelium. , 1987 .

[152]  J. Oates,et al.  2010 – METABOLISM OF THROMBOXANE B2 IN MAN , 1978 .